Prognosis

Gilead CEO Says Over 50,000 Remdesivir Courses Ready to Ship

Company talking with FDA over possible emergency use approval
Gilead is also in discussions how to allocate limited supply

Fauci Says Gilead Data Shows Covid-19 Drug Has 'Clear-Cut' Positive Effect

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Robert Langreth

April 30, 2020 at 2:05 AM UTC

This article is for subscribers only.

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said there are more than 50,000 courses of the company’s experimental Covid-19 therapy, packed in vials and ready to ship as soon as the drug is authorized for emergency use by U.S. regulators.

He made the comments in an interview hours after the National Institute of Allergy and Infectious Diseases director Anthony Fauci said a U.S.-run trial of the drug, remdesivir, met its overall target, helping patients recover faster. The potential for the first effective coronavirus treatment sent stock markets soaring on Wednesday.